AL

Alim Ladha

Principal at MPM BioImpact

Cambridge, Massachusetts

Overview 

Alim Ladha is a Principal at MPM BioImpact in Cambridge, Massachusetts, with a background in research, applied machine learning, and genome editing. With a PhD from MIT and experience at prestigious institutions like the Broad Institute and Finch Therapeutics Group, Ladha excels in collaborative problem-solving and technical and scientific writing. Ladha's career highlights include serving in key roles at MPM BioImpact, Broad Institute, and Finch Therapeutics Group, showcasing expertise in research, analytical skills, and management, along with a strong foundation in molecular biology and mathematical modeling.

Work Experience 

MB

MPM BioImpact

  • Principal

    2024 - Current

  • Senior Associate

    2023 - 2024

  • Associate

    2021 - 2023

MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.

mpmbioimpact.com
BI

Broad Institute of MIT and Harvard

  • Graduate Student

    2018 - 2021

    Graduate student in the lab of Feng Zhang advancing genome editing and molecular diagnostics using CRISPR. Selected inventions and publications: STOPCovid - A streamlined CRISPR-based COVID-19 diagnostic protocol, clinically validated and published in the New England Journal of Medicine. With 93.1% sensitivity and 98.5% specificity, no requirement for advanced instrumentation, and 30 minute time-to-result, STOPCovid provides the performance of complex PCR-based tests with the ease and flexibility of antigen-based tests. Pine Trees Health, a Cambridge-based startup, has raised $50M to commercialize STOPCovid. Covered by the New York Times, MIT News, and USA Today. CAST - a new class of genome editing tools for targeted insertion of large DNA sequences. Originally published in Science, we were the first group to demonstrate the functionality of these systems and their potential for genome editing. In Cell, we described exciting developments about the mechanism of CAST systems relevant for future biotechnological application. Covered by STAT News and MIT News.

MI

Massachusetts Institute of Technology

  • Graduate Teaching Assistant

    2020 - 2020

    Graduate TA for 20.465: Engineering the Immune System in Cancer and Beyond

FT

Finch Therapeutics Group

  • Researcher

    2018 - 2018

    Developed assays for the pre-clinical program FIN-524, a collaboration with Takeda to create a microbiome-based therapeutic for Ulcerative Colitis

DU

Duke University

  • Teaching Assistant

    2017 - 2018

    Undergraduate TA for ECE280 - Signals and Systems

Truskey Lab

  • Undergraduate Researcher

    2017 - 2018

    Pratt Engineering Undergraduate Fellow. Using induced pluripotent stem cells (iPSCs) to model Progeria vascular endothelium in tissue-engineered blood vessels

O

OpenBiome

  • Clinical Researcher

    2016 - 2016

OpenBiome is a nonprofit organization dedicated to expanding safe access to fecal microbiota transplants (FMT), and to catalyzing research.

Raised $125,000.00 from The Draper Richards Kaplan Foundation.

openbiome.org
O

OpenBiome

  • Clinical Researcher

    2015 - 2015

OpenBiome is a nonprofit organization dedicated to expanding safe access to fecal microbiota transplants (FMT), and to catalyzing research.

Raised $125,000.00 from The Draper Richards Kaplan Foundation.

openbiome.org

Education 

Articles About Alim

Relevant Websites